Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma
Background Atezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value for response to immunotherapy in non-HCC cancer types. Our study investigated the effect of BMI on safety and efficacy of real-life use of Atezo/Bev for unresectable HCC. Methods 191 consecutive patients from seven centres receiving Atezo/Bev were included in the retrospective study. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in overweight (BMI ≥ 25) and non-overweight (BMI < 25) patients. Treatment-related adverse events (trAEs) were evaluated. Results Patients in the overweight cohort (n = 94) had higher rates of non-alcoholic fatty liver disease (NAFLD) and lower rates of Hepatitis B compared to non-overweight cohort (n = 97). Baseline Child–Pugh class and Barcelona Clinic Liver Cancer stage were similar between cohorts, with lower rates of extrahepatic spread in the overweight group. Overweight patients had similar OS compared to non-overweight (median OS 15.1 vs. 14.9 months; p = 0.99). BMI did not influence median PFS (7.1 vs. 6.1 months; p = 0.42), ORR (27.2% vs. 22.0%; p = 0.44) and DCR (74.1% vs. 71.9%; p = 0.46). There were higher rates of atezolizumab-related fatigue (22.3% vs. 10.3%; p = 0.02) and bevacizumab-related thrombosis (8.5% vs. 2.1%; p = 0.045) in the overweight patients, but overall trAEs and treatment discontinuation were comparable between cohorts. Conclusion Atezo/Bev has comparable efficacy in overweight HCC patients, with an increase in treatment-related fatigue and thrombosis. Combination therapy is safe and efficacious to use in overweight patients, including those with underlying NAFLD..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Hepatology international - 17(2023), 4 vom: 01. Apr., Seite 904-914 |
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s12072-023-10491-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2144755175 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2144755175 | ||
| 003 | DE-627 | ||
| 005 | 20240118100709.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12072-023-10491-3 |2 doi | |
| 035 | |a (DE-627)OLC2144755175 | ||
| 035 | |a (DE-He213)s12072-023-10491-3-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Vithayathil, Mathew |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Atezolizumab plus bevacizumab (Atezo/Bev) is first line-treatment for unresectable hepatocellular carcinoma (HCC). Body mass index (BMI) has demonstrated predictive value for response to immunotherapy in non-HCC cancer types. Our study investigated the effect of BMI on safety and efficacy of real-life use of Atezo/Bev for unresectable HCC. Methods 191 consecutive patients from seven centres receiving Atezo/Bev were included in the retrospective study. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in overweight (BMI ≥ 25) and non-overweight (BMI < 25) patients. Treatment-related adverse events (trAEs) were evaluated. Results Patients in the overweight cohort (n = 94) had higher rates of non-alcoholic fatty liver disease (NAFLD) and lower rates of Hepatitis B compared to non-overweight cohort (n = 97). Baseline Child–Pugh class and Barcelona Clinic Liver Cancer stage were similar between cohorts, with lower rates of extrahepatic spread in the overweight group. Overweight patients had similar OS compared to non-overweight (median OS 15.1 vs. 14.9 months; p = 0.99). BMI did not influence median PFS (7.1 vs. 6.1 months; p = 0.42), ORR (27.2% vs. 22.0%; p = 0.44) and DCR (74.1% vs. 71.9%; p = 0.46). There were higher rates of atezolizumab-related fatigue (22.3% vs. 10.3%; p = 0.02) and bevacizumab-related thrombosis (8.5% vs. 2.1%; p = 0.045) in the overweight patients, but overall trAEs and treatment discontinuation were comparable between cohorts. Conclusion Atezo/Bev has comparable efficacy in overweight HCC patients, with an increase in treatment-related fatigue and thrombosis. Combination therapy is safe and efficacious to use in overweight patients, including those with underlying NAFLD. | ||
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Anti-programmed death-ligand | |
| 650 | 4 | |a Anti-vascular endothelial growth factor | |
| 650 | 4 | |a Checkpoint inhibitor | |
| 650 | 4 | |a Obesity | |
| 650 | 4 | |a Cirrhosis | |
| 650 | 4 | |a Overall survival | |
| 650 | 4 | |a Progression-free survival | |
| 650 | 4 | |a Overweight | |
| 650 | 4 | |a Non-alcoholic fatty liver disease | |
| 700 | 1 | |a D’Alessio, Antonio |4 aut | |
| 700 | 1 | |a Fulgenzi, Claudia Angela Maria |4 aut | |
| 700 | 1 | |a Nishida, Naoshi |4 aut | |
| 700 | 1 | |a Schönlein, Martin |4 aut | |
| 700 | 1 | |a von Felden, Johann |4 aut | |
| 700 | 1 | |a Schulze, Kornelius |4 aut | |
| 700 | 1 | |a Wege, Henning |4 aut | |
| 700 | 1 | |a Saeed, Anwaar |4 aut | |
| 700 | 1 | |a Wietharn, Brooke |4 aut | |
| 700 | 1 | |a Hildebrand, Hannah |4 aut | |
| 700 | 1 | |a Wu, Linda |4 aut | |
| 700 | 1 | |a Ang, Celina |4 aut | |
| 700 | 1 | |a Marron, Thomas U. |4 aut | |
| 700 | 1 | |a Weinmann, Arndt |4 aut | |
| 700 | 1 | |a Galle, Peter R. |4 aut | |
| 700 | 1 | |a Bettinger, Dominik |4 aut | |
| 700 | 1 | |a Bengsch, Bertram |4 aut | |
| 700 | 1 | |a Vogel, Arndt |4 aut | |
| 700 | 1 | |a Balcar, Lorenz |4 aut | |
| 700 | 1 | |a Scheiner, Bernhard |4 aut | |
| 700 | 1 | |a Lee, Pei-Chang |4 aut | |
| 700 | 1 | |a Huang, Yi-Hsiang |4 aut | |
| 700 | 1 | |a Amara, Suneetha |4 aut | |
| 700 | 1 | |a Muzaffar, Mahvish |4 aut | |
| 700 | 1 | |a Naqash, Abdul Rafeh |4 aut | |
| 700 | 1 | |a Cammarota, Antonella |4 aut | |
| 700 | 1 | |a Zanuso, Valentina |4 aut | |
| 700 | 1 | |a Pressiani, Tiziana |4 aut | |
| 700 | 1 | |a Pinter, Matthias |4 aut | |
| 700 | 1 | |a Cortellini, Alessio |4 aut | |
| 700 | 1 | |a Kudo, Masatoshi |4 aut | |
| 700 | 1 | |a Rimassa, Lorenza |4 aut | |
| 700 | 1 | |a Pinato, David J. |4 aut | |
| 700 | 1 | |a Sharma, Rohini |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology international |d Springer India, 2007 |g 17(2023), 4 vom: 01. Apr., Seite 904-914 |w (DE-627)54812650X |w (DE-600)2393254-5 |w (DE-576)9548126508 |x 1936-0533 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:4 |g day:01 |g month:04 |g pages:904-914 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s12072-023-10491-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 4 |b 01 |c 04 |h 904-914 | ||